Lexapro (Escitalopram Oxalate) Patent Expiration, LOE Window & CMS Spending

Lexapro (Escitalopram Oxalate) by AbbVie: FDA Orange Book LOE 2026-05-12, 12 AB generics, $20.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN021323 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-05-12
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$20.5M
2024 Medicare Part D Spend$17.6M
2024 Medicaid Spend$2.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.